Matthew is a Senior Associate with a strong technical background. He has worked on a number of high profile disputes, where he has been able to utilise his strong technical knowledge to advise clients in the Life Sciences and TMC sectors.
Matthew advises clients across a broad range of intellectual property issues, with particular expertise advising life sciences companies in relation to technical patent disputes. Matthew also acts for clients in the telecoms industry.
He has experience acting on high profile patent disputes in the United Kingdom and the Unified Patent Court, including co-ordinating and harmonising strategy with litigation teams in other European jurisdictions (including parallel European EPO opposition proceedings).
Matthew also assists clients with trade mark enforcement strategies and disputes.
Matthew joined Osborne Clarke as a trainee in 2018 and qualified as an Associate in September 2020. He holds a First-Class Honours degree in Biochemistry from the University of Bristol and Postgraduate Diploma in IP Law from Oxford University, with distinction.
Helping you succeed in tomorrow's world
I have a keen interest in decarbonisation, digitalisation and artificial intelligence. I am particularly interested in helping our clients understand how these transformations intersect with intellectual property rights and how our clients can use their intellectual property to facilitate innovation in these fields.
Insights
The UK Patents Court puts an arrow through Teva's application for declaratory relief
Court of Appeal judge provides obiter guidance on the correct application of Formstein defence in the UK
The decision provides a further example that the UK courts are likely to accept the Formstein defence, when required, and...
Car wars: how tech ownership battles will decide the future leaders of autonomous vehicles
An upsurge in patent filings by new competitors in the autonomous vehicles arena means incumbents need to strengthen their IP...
Patents Court offers guidance on use of doctrine of equivalents
Decision makes it clear that a patentee must consider their infringement position at an early stage in proceedings
Can gene-editing help solve the energy crisis?
What role can biofuels play in fighting climate change and can CRISPR sequencing technology help it reach its potential?
A new bag of tricks? Obvious if it could have been done before (says the Patents Court)
In order to establish obviousness for the purposes of a patent application, it is enough to show that the idea...